Orlistat Market Overview
Global Orlistat Market was valued at USD 3.02 billion in 2021 and is expected to reach USD 4.61 billion by the year 2028, at a CAGR of 6.2%.
The growing number of weight-loss awareness initiatives is likely to be a significant driver for the growth of Orlistat market. Mainly, orlistat is used as an anti-obesity medication. The primary function of Orlistat is to inhibit fat absorption from the human diet. It limits fat absorption by acting as a lipase inhibitor, resulting in a reduction in calorie intake. Orlistat works by blocking pancreatic and gastric lipases, which are enzymes in the gut that break down triglycerides. When lipase activity is inhibited, dietary triglycerides are not digested into absorbable-free fatty acids and instead stay unaltered.
In most of the regions across globe, obesity-related issues have been a growing concern in the recent years. Orlistat also lowers blood pressure and inhibits the formation of type 2 diabetes in obese population. Orlistat medication does not allow an individual to regain lost weight and does not block the absorption of fats from non-fat foods and sugar.
Major Growth Drivers: Orlistat Market
Over the forecasted period, a robust pipeline of the orlistat drug is projected to enhance market growth. Furthermore, Orlistat, developed by the University of Texas South Western Medical Center, has been in phase 2 testing since 2015. Orlistat is a medication used to treat type 1 hyperlipoproteinemia. Lipoprotein lipase deficiency causes hyperlipoproteinemia type 1. The University of Texas South Western Medical Canters’ SLx-4090 is under phase 2 testing to see how well it works in conjunction with Orlistat. SLx-4090 is used to treat elevated blood fat levels, which are most commonly seen in people with hyperlipoproteinemia type 1.
The rising prevalence of obesity and its related diseases is projected to drive orlistat market expansion. According to a National Family Health Survey done in 2015 in India, over 9.8 million men and over 20 million women are obese. India has the world's second-highest rate of obese children, with the number steadily growing by 3-5 million patients per year.
Challenges : Orlistat Market
Health risks such as the risk of psychiatric disorder and stroke are expected to have a negative impact on market growth over the forecast period. Innumerable anti-obesity drugs approved in the last decade, including Knoll and Acomplia (rimonabant), have been withdrawn due to long-term side effects such as suicidal thoughts, depression, and cardiovascular problems. Due to the previously mentioned factors, healthcare providers have a negative impression of anti-obesity drugs and do not recommend them to consumers.
The market for orlistat and anti-obesity drugs is expected to grow slowly due to high attrition rates in the recent years. The transition of therapeutic goods from phase one through market is difficult because more than 80% of drugs are discontinued before reaching pre-registration. It will result in a low number of representative drugs in later stages of development.
Market Segmentation
Geographically, Asia-Pacific accounted for the largest market share in 2017 and is anticipated to maintain its dominance by the end of 2023. Asia-Pacific is expected to exhibit the highest CAGR of 6.3% over the forecast period.
Players Covered in Orlistat Market are :
- Roche
- GSK group
- Teva
- Sandoz(Novartis)
- STADA-VN J.V.Co. Ltd
- Hexal AG
- National Company for Pharmaceutical Industry
- Lunan Pharmaceutical Group Corporation
- ZEIN pharmaceutical
- HISUN
- Taj Pharmaceuticals Ltd
- Kabir Life Sciences & Research
- DM Pharma
- China Zhongshan Pharm and other major players.
Global Orlistat Market |
|||
Base Year: |
2021 |
Forecast Period: |
2022-2028 |
Historical Data: |
2016 to 2020 |
Market Size in 2021: |
USD 3.02 Bn. |
Forecast Period 2022-28 CAGR: |
6.2% |
Market Size in 2028: |
USD 4.61 Bn. |
Segments Covered: |
By Type |
|
|
By Distribution Channel |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Distribution Channel
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Orlistat Market by Type
5.1 Orlistat Market Overview Snapshot and Growth Engine
5.2 Orlistat Market Overview
5.3 120 mg
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 120 mg: Grographic Segmentation
5.4 60 mg
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 60 mg: Grographic Segmentation
Chapter 6: Orlistat Market by Distribution Channel
6.1 Orlistat Market Overview Snapshot and Growth Engine
6.2 Orlistat Market Overview
6.3 Hospital Pharmacies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Pharmacies: Grographic Segmentation
6.4 Online Pharmacies
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Online Pharmacies: Grographic Segmentation
6.5 Retail Pharmacies
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Retail Pharmacies: Grographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Orlistat Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Ansoff Matrix
7.1.5 Orlistat Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Orlistat Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ROCHE
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 GSK GROUP
7.4 TEVA
7.5 SANDOZ(NOVARTIS)
7.6 STADA-VN J.V.CO. LTD
7.7 HEXAL AG
7.8 NATIONAL COMPANY FOR PHARMACEUTICAL INDUSTRY
7.9 LUNAN PHARMACEUTICAL GROUP CORPORATION
7.10 ZEIN PHARMACEUTICAL
7.11 HISUN
7.12 TAJ PHARMACEUTICALS LTD
7.13 KABIR LIFE SCIENCES & RESEARCH
7.14 DM PHARMA
7.15 CHINA ZHONGSHAN PHARM
7.16 OTHER MAJOR PLAYERS
Chapter 8: Global Orlistat Market Analysis, Insights and Forecast, 2016-2028
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 120 mg
8.2.2 60 mg
8.3 Historic and Forecasted Market Size By Distribution Channel
8.3.1 Hospital Pharmacies
8.3.2 Online Pharmacies
8.3.3 Retail Pharmacies
Chapter 9: North America Orlistat Market Analysis, Insights and Forecast, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 120 mg
9.4.2 60 mg
9.5 Historic and Forecasted Market Size By Distribution Channel
9.5.1 Hospital Pharmacies
9.5.2 Online Pharmacies
9.5.3 Retail Pharmacies
9.6 Historic and Forecast Market Size by Country
9.6.1 U.S.
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Europe Orlistat Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 120 mg
10.4.2 60 mg
10.5 Historic and Forecasted Market Size By Distribution Channel
10.5.1 Hospital Pharmacies
10.5.2 Online Pharmacies
10.5.3 Retail Pharmacies
10.6 Historic and Forecast Market Size by Country
10.6.1 Germany
10.6.2 U.K.
10.6.3 France
10.6.4 Italy
10.6.5 Russia
10.6.6 Spain
10.6.7 Rest of Europe
Chapter 11: Asia-Pacific Orlistat Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 120 mg
11.4.2 60 mg
11.5 Historic and Forecasted Market Size By Distribution Channel
11.5.1 Hospital Pharmacies
11.5.2 Online Pharmacies
11.5.3 Retail Pharmacies
11.6 Historic and Forecast Market Size by Country
11.6.1 China
11.6.2 India
11.6.3 Japan
11.6.4 Singapore
11.6.5 Australia
11.6.6 New Zealand
11.6.7 Rest of APAC
Chapter 12: Middle East & Africa Orlistat Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 120 mg
12.4.2 60 mg
12.5 Historic and Forecasted Market Size By Distribution Channel
12.5.1 Hospital Pharmacies
12.5.2 Online Pharmacies
12.5.3 Retail Pharmacies
12.6 Historic and Forecast Market Size by Country
12.6.1 Turkey
12.6.2 Saudi Arabia
12.6.3 Iran
12.6.4 UAE
12.6.5 Africa
12.6.6 Rest of MEA
Chapter 13: South America Orlistat Market Analysis, Insights and Forecast, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 120 mg
13.4.2 60 mg
13.5 Historic and Forecasted Market Size By Distribution Channel
13.5.1 Hospital Pharmacies
13.5.2 Online Pharmacies
13.5.3 Retail Pharmacies
13.6 Historic and Forecast Market Size by Country
13.6.1 Brazil
13.6.2 Argentina
13.6.3 Rest of SA
Chapter 14 Investment Analysis
Chapter 15 Analyst Viewpoint and Conclusion
Global Orlistat Market |
|||
Base Year: |
2021 |
Forecast Period: |
2022-2028 |
Historical Data: |
2016 to 2020 |
Market Size in 2021: |
USD 3.02 Bn. |
Forecast Period 2022-28 CAGR: |
6.2% |
Market Size in 2028: |
USD 4.61 Bn. |
Segments Covered: |
By Type |
|
|
By Distribution Channel |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Frequently Asked Questions :
The forecast period in the Orlistat Market research report is 2022-2028.
Roche, GSK group, Teva, Sandoz (Novartis), STADA-VN J.V. Co. Ltd, Hexal AG, National Company for Pharmaceutical Industry, Lunan Pharmaceutical Group Corporation, ZEIN pharmaceutical, HISUN, Taj Pharmaceuticals Ltd, Kabir Life Sciences & Research, DM Pharma, China Zhongshan Pharm, and other major players.
The Orlistat Market is segmented into Type, Distribution Channel, and region. By Type, the market is categorized into 120 mg and 60 mg. By Distribution Channel, the market is categorized into Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. By region, it is analyzed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
Orlistat is a drug that is basically designed to treat obesity. Its primary function is to prevent absorption of fat from the food or diet consumed by humans.
The Orlistat Market was valued at USD 3.02 Billion in 2021 and is projected to reach USD 4.61 Billion by 2028, growing at a CAGR of 6.2% from 2022 to 2028.